W C Shakespeare
Overview
Explore the profile of W C Shakespeare including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dalgarno D, Metcalf Jr C, Shakespeare W, Sawyer T
Curr Opin Drug Discov Devel
. 2009 Aug;
3(5):549-64.
PMID: 19649883
Signal transduction targets include catalytic and/or non-catalytic domains, which are critical to various aspects of cell growth, differentiation, metabolism and function, mitogenesis, motility and gene transcription. Specific examples of molecular...
2.
Sawyer T, Shakespeare W, Wang Y, Sundaramoorthi R, Huang W, Metcalf 3rd C, et al.
Med Chem
. 2006 Jun;
1(3):293-319.
PMID: 16787325
Protein phosphorylation has been exploited by Nature in profound ways to control various aspects of cell proliferation, differentiation, metabolism, survival, motility and gene transcription. Cellular signal transduction pathways involve protein...
3.
Lesslie D, Summy J, Parikh N, Fan F, Trevino J, Sawyer T, et al.
Br J Cancer
. 2006 May;
94(11):1710-7.
PMID: 16685275
Vascular endothelial growth factor (VEGF) is the predominant pro-angiogenic cytokine in human malignancy, and its expression correlates with disease recurrence and poor outcomes in patients with colorectal cancer. Recently, expression...
4.
Kawahata N, Yang M, Luke G, Shakespeare W, Sundaramoorthi R, Wang Y, et al.
Bioorg Med Chem Lett
. 2001 Aug;
11(17):2319-23.
PMID: 11527723
The novel phosphotyrosine (pTyr) mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp) has been designed and incorporated into a series of nonpeptide inhibitors of the SH2 domain of pp60(c-Src) (Src) tyrosine kinase. A 2.2 A...
5.
Shakespeare W
Curr Opin Chem Biol
. 2001 Jul;
5(4):409-15.
PMID: 11470604
The past two years have witnessed a number of significant advances in the design of SH2 inhibitors of both Src and Grb2. For Src, several non-peptide templates have been developed...
6.
Bohacek R, Dalgarno D, Hatada M, Jacobsen V, Lynch B, Macek K, et al.
J Med Chem
. 2001 Mar;
44(5):660-3.
PMID: 11262076
No abstract available.
7.
Violette S, Guan W, Bartlett C, Smith J, Bardelay C, Antoine E, et al.
Bone
. 2001 Feb;
28(1):54-64.
PMID: 11165943
Src, a nonreceptor tyrosine kinase, is an important regulator of osteoclast-mediated resorption. We have investigated whether compounds that bind to the Src SH2 domain inhibit Src activity in cells and...
8.
Shakespeare W, Bohacek R, Azimioara M, Macek K, Luke G, Dalgarno D, et al.
J Med Chem
. 2000 Oct;
43(21):3815-9.
PMID: 11052784
No abstract available.
9.
Violette S, Shakespeare W, Bartlett C, Guan W, Smith J, Rickles R, et al.
Chem Biol
. 2000 Mar;
7(3):225-35.
PMID: 10712930
Background: The observations that Src(-/-) mice develop osteopetrosis and Src family tyrosine kinase inhibitors decrease osteoclast-mediated resorption of bone have implicated Src in the regulation of osteoclast-resorptive activity. We have...
10.
Shakespeare W, Bohacek R, Narula S, Azimioara M, Yuan R, Dalgarno D, et al.
Bioorg Med Chem Lett
. 1999 Nov;
9(21):3109-12.
PMID: 10560734
A CuBr-mediated, regioselective cross-coupling between methyl 2,5-diiodobenzoate (4) and [(diethoxyphosphinyl)difluoromethyl]zinc bromide is reported. Palladium-catalyzed incorporation of an amino acid side chain, followed by subsequent modifications resulted in the rapid construction...